The Future of International Drug Control

Special Section: Health, Rights, and the Future of Global Drug Control

VIRTUAL ROUNDTABLE

Julie Hannah

More than a century after its foundations were laid, the international drug control system faces fundamental questions about what it has achieved, whose interests it serves, and whether it remains fit for the contemporary world.

This roundtable brings together five contributors with distinct experiential and regional vantage points:

  • Sandeep Chawla, former deputy executive director of the United Nations Office on Drugs and Crime (UNODC), draws on decades within the United Nations (UN) system to examine its institutional history and governance.
  • Alison Crockett, a former UN official and senior official within the Scottish government’s Drugs Policy Division, interrogates the political and social inequalities that shape drug policy.
  • Kojo Koram, a legal scholar and activist, brings a political economy perspective to questions of power, racial justice, and emerging legal markets.
  • Gloria Lai, a civil society leader advancing drug policy reform, reflects on the experience of punitive drug policies and reform efforts across Southeast Asia.
  • Marta Machado, a legal scholar and Brazil’s national secretary for drug policy, draws on her country’s experience of integrating human rights, development, and public security.

Together, they reflect on the assumptions and institutions that have shaped international drug control and explore what might be worth preserving, rethinking, or fundamentally changing.

Where should international drug control go now?

Julie: International drug control was established around the promise of protecting health and welfare. More than a century later, how should we assess that promise and the system that developed around it? Drawing on your own experiences, what direction should international drug control take now?

Sandeep: One of the most significant issues is the history of the system. “Control” is itself an unfortunate term. There is an older colonial lineage, certainly, but what is not given sufficient attention is that the country which dominated modern drug control, and had almost a monopoly stake in how the system was designed, was the United States. The United States made international drug control an instrument of its domestic policy. From the early 20th century, concerns about opium, Chinese labor and immigration, and later temperance and prohibition were projected internationally. So the colonial character of the modern system is very closely connected to US influence: controlling the supply of drugs coming into the United States and those associated with populations and territories outside the West, while drawing distinctions between “our” drugs and “their” drugs.

That policy orientation was institutionalized through the Single Convention on Narcotic Drugs. Health was put to the side, largely under the purview of the World Health Organization (WHO), while an entire machinery of drug control developed separately, centered in Vienna. Policy came to be made through the Commission on Narcotic Drugs, largely by diplomats, with technical expertise supplied by UNODC. WHO and UNODC may now work together, but WHO still has comparatively little voice.

UNODC itself cannot easily change a system on which its institutional existence depends. Added to that is its dependence on earmarked funding from a small number of donor countries, including those most interested in maintaining the system as it is, which inevitably shapes what can be done.

I think the direction has to be toward health and human rights. A century of draconian supply control has generated as many problems as it has solved. We have tried that model. It has not worked. We should be trying something else.

Alison: The premise that international drug control was ever about health bears very little scrutiny, given the damage it has caused to so many people’s lives. In fact, I think it had very little to do with “drug control” in any shape or form and was much more about economic and political power and control.

Countries regularly adopt positions in blocs—whether the European Union, the Group of Western European and Other States, or the G77—and the same dynamics play out whether they are talking about corruption, human rights, drugs, or any other matter. Drug cultivation and use are inextricably bound to poverty and inequality, not only in poorer countries but also among poorer communities in wealthy countries. Drug strategies are often used as a stick to beat people and blame them for problems caused by political decisions.

If the international community is serious about the health and welfare of its citizens, inequality must have far greater prominence. WHO cannot simply be seen as the next best alternative to UNODC, as this risks turning drug use into a medical issue rather than recognizing that it is largely a social one.

Kojo: For me, protecting health means accepting that prohibition has failed to live up to its own explicit promises. It has not led to declining drug use, drug-related deaths, or drug harms. But moving into the future requires more than simply retreating from prohibition.

Even legalization has seen some of the hierarchies produced through the drug war reappear in new forms, with substances still being policed in poor and racialized communities becoming lucrative commodities for others. Legal regulation is necessary, but we need regulation designed around public health rather than private profit, and which takes seriously the debts owed to communities that bore the heaviest costs of enforcement, often poor and racially marginalized communities and those in the Global South.

The question is therefore also about who benefits from reform and whether the structures of power and inequality created through prohibition are being dismantled or simply reproduced in new markets.

Gloria: I think the international drug control system needs reforms in which a health and human rights approach to people who use drugs is no longer presented as an option for governments—for example, as an alternative to punishment through criminalization or incarceration—but as an obligation.

The evidence of the damage wrought by punitive approaches, underpinned by self-serving political narratives, is painfully clear throughout Southeast Asia: extrajudicial killings, over-investment in law enforcement at the expense of life-saving harm reduction responses, and over-incarceration in prisons and drug detention centers.

Improving health outcomes requires creating space for them by removing the barriers posed by criminalization, punishment, stigma, and discrimination. We need to prioritize funding for research, consultations, pilot testing, evidence-based policy reforms, implementation, and evaluation in ways that are inclusive of people who use drugs from diverse and intersecting backgrounds.

Marta: First, I think the international drug control system needs to go back to the evidence. If we look honestly at the evidence, we will see that the system has caused more harm than it has solved in terms of the health and public security challenges we face as a global community. The promises have not been fulfilled. Instead, we have created further inequalities, harm, and violence.

Second, we need to recognize that protecting health is about much more than health services. We have to look at the social determinants of health, including racial and gender inequalities, violence, and social vulnerabilities. This is very much aligned with approaches we have been trying to advance here in Brazil, working with communities and territories and establishing a more comprehensive understanding of prevention. This goes beyond substance use to consider territorial vulnerabilities and different forms of violence related to illicit markets, including state violence.

There is no single solution that will work for everyone. Yet the current international system continues to favor standardized responses and technical packages that fail to meaningfully engage with these broader social, political, and economic realities. It also constrains the freedom of countries to determine their own approaches, experiment with more progressive solutions, and respond to the particular circumstances of their populations.

Many drug control measures have been justified in the name of protecting health, yet they have criminalized people and isolated them from their communities. We have data showing that militarized operations in communities, for example, can have enormous consequences for health and well-being, including the closure of schools and disruption of everyday life.

In many ways, the current system works against the very protection of health it was intended to achieve.

What should we preserve, and what should we leave behind?

Julie: If we accept that the international drug control system needs fundamental change, what, if anything, is worth preserving and what needs to be left behind?

Sandeep: What is worth preserving is what the system was originally designed for: the protection of health. Drugs like morphine can be life-threatening when misused, but they are also essential medicines. Morphine is one of the oldest and most widely used medicines in the world. Most is produced in just a few countries, so we need an international system to manage its trade and ensure that it reaches other countries. That system actually works and is well worth preserving. But we don’t need a whole supply control regime to do it. The scheduling system should also be kept, but cleaned up and made more rational.

The problem is what happened in practice. Political pressure and all kinds of supply-side interventions turned what was meant to be a health system into a prohibition system. We need to leave behind control by diplomats, lawyers, and law enforcement officials, while health and human rights experts have very little say. WHO makes recommendations, but the Commission on Narcotic Drugs makes the decisions, often through civil servants rather than medical experts. WHO needs a much bigger voice.

We also need to abandon the assumption that controlling supply through enforcement will work. The pressure falls on small producers and low-level dealers, while the big trafficking organizations carry on, often protected by corruption. You will never get rid of the market that way.

Alison: Drugs have always been a feature of the human condition, used in many ways and for many reasons, many of which are life-saving and life-affirming. For some people who have suffered trauma, poverty, and multiple disadvantages, drugs have become a solution to their situation, while sometimes exacerbating problems in already difficult lives.

The international drug control system should focus first on human rights-based approaches to helping people who find themselves in this position. These approaches should be shaped and led by those worst affected by previous efforts to prohibit drug cultivation and use, taking a holistic, person-centered approach that provides the support that people request in ways they can use. There is already a strong and growing community that could lead this.

Solutions should be connected to other services that affect people’s quality of life, including housing, primary health care, and mental health support.

What needs to be left behind is the demonization of drugs as inherently bad or dangerous, and the blame and stigmatization of people who use them. International drug control should not be determined by politicians or officials with vested interests in the status quo, but by the voices of those affected and those who have sought to gather objective, qualitative evidence of what works.

Kojo: What should be left behind is the assumption that punishment protects health. The system has measured success in seizures, arrests, and eradicated crops rather than lives saved or communities strengthened. It has drawn lines between acceptable and dangerous substances that often reflect cultural and racial hierarchies more than evidence, criminalizing traditional practices such as coca chewing while tolerating alcohol and tobacco.

Perhaps the one thing worth preserving from a century of failed prohibition is the international cooperation mobilized to enact it. We need that same global ambition to redesign the system around racial justice, environmental justice, and public health. But I do not think the existing treaties are fit for purpose. The Single Convention made promises about protecting humanity from the harms of drugs, yet the vision of a drug-free world promoted by the UN in 1998 has not materialized.

Ideally, we would reform the treaties and restructure the balance of power within international institutions. But that would require a level of consensus which I think will be extremely difficult to achieve.

The treaties provided the architecture for prohibition, but their enforcement depended heavily on US hegemony and American funding of counternarcotics programs around the world. I do not see countries such as China, Russia, or Iran taking on that same global enforcement role.

What we may see instead is a bifurcated international system, with some countries increasingly abandoning compliance with the treaties while others continue using them to justify draconian enforcement. That may be a more likely future than formal treaty reform, even if reform remains the goal.

Gloria: The international drug control treaties established the health and welfare of all people as their ultimate goal. Yet this goal is hardly reflected in the drug policies of most countries. Instead, many governments focus on reducing the use and supply of drugs, with many in Asia still pledging to achieve “drug-free” status and relying on punishment and law enforcement as their main tools. Decades of failed policies have cost millions of lives and billions of dollars without convincing evidence of improved health and welfare.     

The goal remains worth preserving, but the tools must change. International cooperation can help when it supports human rights and involves affected communities. The UN Joint Programme on Human Rights in the Philippines, implemented between 2020 and 2024, helped encourage a shift toward a human rights approach to drug policy. The inclusion of civil society and people with lived experience, together with shared responsibility across UN agencies, particularly the Office of the United Nations High Commissioner for Human Rights, was critical.

By contrast, international assistance focused exclusively on law enforcement, including training and meetings of law enforcement officers, can hinder reform, especially where accountability and oversight are weak. Such assistance, if internationally funded, must involve agencies and civil society organizations capable of ensuring accountability.

We need to preserve international cooperation while fundamentally changing its purpose, its approach to accountability, and the actors involved.

Marta: We need to leave behind the top-down approach and move toward community-led responses, building national strategies that elevate the voices of those who have been left behind. The militarized approach, fragmented interventions, and hyper-fixation on substances rather than people should all be left behind.

There are, however, some unfulfilled promises worth preserving. The commitment to an integrated and balanced approach, recognizing the need for a range of interventions, remains important. We should preserve international cooperation and standards, particularly the growing recognition of the intersection between human rights and drug policy. We are seeing some governments move away from these commitments, and we must protect them.

The same applies to development. It was never really central to international drug control, but the commitments in the outcome document from the UN General Assembly Special Session on drugs represent important progress. In Brazil, debates about sustainable alternative development in urban and rural areas have helped advance a more robust understanding of rights-based drug policy addressing territorial vulnerabilities and inequalities.

We must also move beyond fragmented technical assistance. The United Nations Development Programme, the Joint United Nations Programme on HIV/AIDS, and the Office of the United Nations High Commissioner for Human Rights are critical to our work in Brazil and should have much stronger roles in any future system.

Finally, we must fundamentally reconsider approaches to public security and organized crime. Militarized responses have failed to confront organized crime effectively while disproportionately affecting vulnerable communities. We need targeted, intelligence-led approaches, grounded in meaningful international cooperation and responsive to countries’ actual needs rather than external pressures. We must leave behind the performative approach to security that the international system continues to enable.

What would we build differently, and how would we know it is working?

Julie: All of you have emphasized the importance of putting people first and ensuring that health and human rights are respected, protected, and fulfilled. If we were designing an international approach to drugs today, what would we build differently, and how would we know it was working?

Sandeep: For me, the fundamental purpose of a drug control system has to be the protection of health. Human rights are important, and they must go hand in hand with public health. Otherwise, we risk repeating the problems we have with two other major psychoactive substances: alcohol and tobacco.

Nicotine is just as addictive as heroin, and alcohol is closely associated with violence, yet both have largely been left to commercial interests. We knew about the link between tobacco and cancer for decades before international controls were introduced. If we take a selective approach to human rights, rather than a more holistic one, we risk allowing commercial interests to take over. We are already seeing this danger with cannabis. Any new system must ensure that commercial interests are not in the driving seat.

How would we know it is working? We need to measure outcomes over the long term, 20 years or more, and undertake much more epidemiological research. We remain desperately short of proper studies on the long-term effects of both old and new substances. Illegality has made much of this research difficult. Things are improving in terms of data and knowledge, but we still have a long way to go. Modern systems of evaluating how new policies actually work must be central to any future approach.

Alison: If I were to build an international approach to drugs today, it would be led by communities of people who use or cultivate drugs, together with their families, neighbors, and others affected. It would focus on the roots of problems rather than their symptoms, including poverty, isolation, and hopelessness.

It would create an environment for sharing knowledge about substances and how to minimize the harms associated with their use. It would provide accurate, evidence-based information that is accessible and easy to understand, including information about the range of substances available and their potential risks.

It would also provide guidance to communities about how to organize, empower themselves, and influence policy makers, drawing on examples of good practice from around the world. It would help people identify practical ways to improve services and support using the resources already available, rather than assuming that additional funding is always the only solution.

Importantly, it would facilitate mutual support among communities still demonized by their governments and stand in solidarity with them. It would help articulate common issues and values that communities could use as the basis for collective action and mutual support.

Success should be understood in terms of whether people have greater control over their lives, access to the support they need, and the ability to shape the policies that affect them.

Kojo: Starting from human rights would mean beginning with people rather than substances. Instead of ranking drugs by perceived danger and building enforcement around that hierarchy, we would ask what people who use, grow, and trade drugs need to live safely and with dignity.

I share the concerns about commercialization. We are already seeing drugs such as cannabis and psychedelics transition into traditional corporate models of commercial delivery, which risk reproducing the inequalities created by prohibition. For me, as a political economist, this makes market design particularly important. How can we design the architecture of regulation, at the point of legislation, to produce different types of markets?

There are a number of possibilities. Communities historically harmed by prohibition could be prioritized for licenses to operate legal businesses. Patients and people who have been criminalized could be represented on company boards. We could require public-interest companies whose founding agreements commit them to spending revenue on repairing the harms of prohibition. Governments also have considerable leverage over how tax revenues are distributed.

We could establish requirements around open access to data and intellectual property, rather than simply allowing biotech companies to obtain exclusive rights over emerging markets. Cooperative models, such as those being implemented in Rhode Island, and cannabis social clubs in Germany and Barcelona, offer other alternatives to traditional corporate structures.

These are choices that need to be made when regulation is designed. Legalization alone will not deliver justice if the same communities continue to be excluded from ownership and decision-making while others profit. We need to put those most harmed by prohibition front and center, including in determining who controls emerging markets and who benefits from reform.

Gloria: Drug policies must be grounded in evidence of what works for people’s health and welfare, rather than political interests, scaremongering, and simplistic rhetoric. Decisions about interventions should begin with evidence of their effects on people’s lives, supported by local data, research, and analysis. Policy design and implementation must comply with international human rights standards and involve people with lived experience. Independent, regular, and transparent monitoring and evaluation should measure progress toward improved health and social outcomes.

International agencies also need to work differently. UNODC, WHO, the Joint United Nations Programme on HIV/AIDS, the United Nations Development Programme, and other relevant agencies should provide joint, evidence-based advice in accordance with the 2018 UN Common Position on Drugs, particularly on steps toward decriminalization, harm reduction, and improved human rights outcomes.

Crucially, they should champion the inclusion of civil society and community stakeholders with lived experience in national policymaking processes. Government officials and political representatives often occupy their positions for only a few years, while civil society and community organizations hold sustained knowledge of the impacts of drugs and drug policies. They are often the foremost experts on the realities facing affected communities, including women, young people, LGBTQ+ people, and people who use drugs.

These stakeholders must be critical decision-makers, including in setting priorities and determining where resources are directed, rather than simply being consulted. Otherwise, we risk continuing to waste resources on policies grounded in deterrence through punishment and an overriding ambition to reduce drug markets, regardless of the harms caused.

Marta: Moving forward, we must design a framework centered on people, communities, and territories, grounded in sustainable development, human rights, and evidence. We should also build much stronger connections across the broader UN system to support this approach.

We need to put people and territories at the center. It is about people, but also the territories and ecosystems in which we are born, live, and thrive. Strengthening territories and communities is critical to ensuring access to rights and addressing the vulnerabilities and inequalities that can contribute to problematic drug use or recruitment into organized crime. This allows us to think about drug policy much more broadly than drugs themselves. Ultimately, our goals should be about improving people’s lives and well-being.

In Brazil, we are developing the concept of comprehensive prevention systems, which reflects this broader understanding. It also requires us to fundamentally rethink how we measure success. Today, drug policies are largely evaluated through indicators such as prevalence and seizures, which tell us very little about whether we are improving people’s lives.

We have been examining the vulnerabilities of Indigenous communities to organized crime, including through the development of an index to better understand these vulnerabilities. This kind of approach allows for continuous learning and ongoing dialogue with communities about their needs and experiences.

We need policies that respond to the realities of communities and territories, are designed and implemented with social participation, strengthen communities’ existing capacities, and are based on effective multisectoral approaches. This is how we build good public policy, and drug policy should be no different.

Julie: These perspectives reflect shared concerns and a diversity of views on the future of international drug control. They raise critical questions about whether existing treaties and institutions can deliver on their intended purpose, who should shape drug policy, and how new approaches can avoid reproducing systematic harms and inequalities. There is certainly no single solution for what comes next. How we proceed requires us to seriously consider how much of the past we are prepared both to learn from and to leave behind to create space for a different future.

Julie Hannah is a lecturer in law at the Human Rights Centre, University of Essex, and co-director of the International Centre on Human Rights and Drug Policy, Colchester, UK.

Please address correspondence to the author. Email: jhanna@essex.ac.uk.

Competing interests: None declared.

Copyright © 2026 Hannah. This is an open access article distributed under the terms of the Creative Commons Attribution-Noncommercial License (http://creativecommons.org/licenses/by-nc/4.0/), which permits unrestricted noncommercial use, distribution, and reproduction in any medium, provided the original author and source are credited.